Design and Characterization of Bivalent Molecules Against SARS-CoV2

Abstract

Abstract The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compelled extraordinary attention to the development of therapeutic reagents. The favorable physical properties of nanobodies make them attractive candidates for investigations of their ability to block viral entry. By X-ray crystallography we determined the structural basis of the interaction of a panel of synthetic nanobodies (Sb14, Sb16, Sb45 and Sb68) with the SARS-CoV-2 receptor binding domain (RBD): binary complexes of Sb16–RBD and Sb45–RBD; a ternary complex of Sb14–RBD–Sb68, and Sb45–RBD–Sb68. Sb16 and Sb45 bind the RBD with identical footprints with ACE2, but their complementarity determining regions (CDR)2 and CDR3 are oriented diametrically oppositely. The ternary structure of the Sb45-RBD-Sb68 complex indicates that Sb45 binds squarely at the ACE2 interface, whereas Sb68 attaches toward the ACE2 interface's perimeter. The ternary configuration suggests that several sybodies may capture a sizable portion of the RBD's surface. These sybody structures provided structural insights that were used to create novel, highly potent biparatopic nanobodies and bivalent molecules with ACE2 and ACE2 binding scaffold mimicking miniproteins that bind the RBD with high affinity and neutralize SARS-CoV-2 and variants. Supported by the Intramural research program of the NIAID/NIH